Phase 2 N=7 Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
Breast Cancer · Chronic Pain Due to Malignancy (Finding)
Primary: Overall Pain Relief. — 1.9; 0.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=252 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Advanced Unresectable or Metastatic Solid Malignancy
Primary: Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response…
Phase 2 N=28 Developing Oral LT3 Therapy for Heart Failure - HFpEF
Heart Failure With Preserved Ejection Fraction · Low Triiodothyronine Syndrome
Primary: Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats — 10; 12 Number of participants with events
Phase 2 N=309 A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
Meningococcal Vaccine
Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…
Phase 2 N=30 Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure
Primary: Change in Exercise Pulmonary Capillary Wedge Pressure (PCWP) — -1; -4 mmHg — p=0.040
Phase 2 N=126 N-Acetylcysteine for Adolescent Alcohol Use Disorder
Alcohol Use Disorder
Primary: Alcohol Use During the Final 4 Weeks of Treatment (Weeks 5 - 8) — 37.9; 42.6 Standard drinks
Phase 2 N=45 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
X-Linked Retinitis Pigmentosa
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…
Phase 2 N=134 Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Rheumatoid Arthritis
Primary: Normal Limits of TUVjoint in Healthy Subjects
Phase 2 N=56 Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
Anxiety Disorder · Depression · Recurrent Breast Cancer
Primary: Changes in Center for Epidemiological Studies Depression Scale (CES-D) Scores — 0.57; -3.18 score on a scale
Phase 2 N=27 Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants
Phase 2 N=155 A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
Healthy
Primary: Main Study: Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 7 Days Post-vaccination 1 — 21; 78; 6; 20 Participants
Phase 2 N=20 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Phase 2 N=40 Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Solid Tumors
Primary: Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs) — 7; 14 Participants
Phase 2 N=20 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
Myositis · Interstitial Lung Disease
Primary: % Predicted Forced Vital Capacity (FVC) Absolute Change — -1.70; -2.05 % predicted FVC — p=<0.05
Phase 2 N=21 Scleroderma Treatment With Autologous Transplant (STAT) Study
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants